ArticleInternational journal of dermatology2026
Minimal Disease Activity as A New Therapeutic Target in Atopic Dermatitis: A 5-Year Real-Life Experience With Dupilumab.
Article in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 48-Week Real-World Atopic Dermatitis Study on Minimal Disease Activity, Associated Factors, and Agreement Between Clinician- and Patient-Reported Outcomes.Dermatology and therapy · 2026Article
- Association between severity of different body regions and inadequate control of atopic dermatitis: results from a cross-sectional and longitudinal study.Frontiers in allergy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis (AD) is a chronic inflammatory skin disease with significant physical and psychosocial burden. Dupilumab, a monoclonal antibody targeting IL-4Rα, has proven to be effective for moderate-to-severe AD, but long-term real-world data remain limited.
objectiveThe aim of this study is to evaluate the long-term effectiveness, safety, and achievement of minimal disease activity (MDA) in patients with moderate-to-severe AD treated with dupilumab over a 5-year period.
methodsA retrospective single-center cohort study was conducted at the Dermatologic Clinic of the University of Turin, including 583 patients aged ≥ 6 years treated with dupilumab between November 2018 and January 2025. Effectiveness was measured by Eczema Area and Severity Index (EASI), Pruritus-Numerical Rating Scale (P-NRS), and Sleep Loss-Numerical Rating Scale (S-NRS) scores, Dermatology Life Quality Index (DLQI). MDA was defined as EASI-90 combined with P-NRS ≤ 1. Safety and drug survival were also assessed.
resultsDupilumab treatment resulted in significant and sustained reductions in EASI and symptom scores over 5 years. The proportion of patients achieving MDA increased from 22.0% at 16 weeks to 56.0% at 208 weeks and remained stable at 55.3% through 5 years. Male sex and childhood onset may reduce treatment success, warranting further study. The safety profile was favorable, with low discontinuation rates, and conjunctivitis as the most common adverse event.
conclusionOur long-term real-world data support the sustained effectiveness and safety of dupilumab in moderate-to-severe AD, with over 55% of patients achieving and maintaining MDA at 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.